FrancophonIA/ELRC3.0 huggingface dataset:
English: • increased blood sugar or uric acid levels in the blood, high blood fat values of triglycerides
Danish: • forhøjede niveauer af blodsukker eller urinsyre i blodet, høje niveauer af blodfedt, triglycerider
English: • a heart rhythm disorder, abnormal pulse
Danish: • en hjerterytmeforstyrrelse, unormal puls
English: Check serum lipase every 2 weeks for the first 2 months and then periodically thereafter.
Danish: Serumlipase skal kontrolleres hver 2. uge i de første 2 måneder og derefter jævnligt.
English: Overall, the most common adverse reactions (≥20%) were platelet count decreased, rash, dry skin, and abdominal pain.
Danish: Generelt var de hyppigste bivirkninger (≥ 20 %) nedsat trombocyttal, udslæt, tør hud og abdominalsmerter.
English: Of the CP-CML patients with no mutation detected at entry, 46% (63/136) achieved a MCyR.
Danish: Ud af de CP-CML-patienter uden konstateret mutation ved indtræden i forsøget opnåede 46 % (63/136) et MCyR.
English: Blast Phase CML
Danish: CML i blastfase
English: Table 3 Adverse reactions observed in CML and Ph+ ALL patients - frequency reported by incidence of treatment emergent events System organ class
Danish: Tabel 3 Bivirkninger observeret hos CML- og Ph+ ALL-patienter - hyppighed er rapporteret efter forekomst af behandlingsopståede bivirkninger Systemorganklasse
English: The most common serious adverse reactions >1% (treatment-emergent frequencies) were pancreatitis (5.6%), pyrexia (4.2%), abdominal pain (4.0%), myocardial infarction (3.6%), atrial fibrillation (3.3%), anaemia, (3.3%), platelet count decreased (3.1%), febrile neutropenia (2.9%), cardiac failure (2.0%), lipase increased (1.8%), dyspnea (1.6%), diarrhoea (1.6%), neutrophil count decreased (1.3%), pancytopenia (1.3%), and pericardial effusion (1.3%).
Danish: De hyppigste alvorlige bivirkninger >1 % (behandlingsrelaterede hyppigheder) var pancreatitis (5,6 %), pyreksi (4,2 %), abdominalsmerter (4,0 %), myokardieinfarkt (3,6 %), atrieflimren (3,3 %), anæmi (3,3 %), nedsat trombocyttal (3,1 %), febril neutropeni (2,9 %), hjerteinsufficiens (2,0 %), forhøjet lipase (1,8 %), dyspnø (1,6 %), diarré (1,6 %), nedsat neutrofiltal (1,3 %), pancytopeni (1,3 %) og perikardie-effusion (1,3 %).
English: In the phase 2 trial, dose reductions were recommended following adverse events; in addition in October 2013 new recommendations for prospective dose reduction in all CP-CML patients in the absence of adverse events were introduced in this trial with the aim of reducing the risk of vascular occlusive events.
Danish: I fase 2-forsøget blev dosisreduktioner anbefalet efter bivirkninger; endvidere blev der i oktober 2013 indført nye anbefalinger for prospektiv dosisreduktion hos alle CP-CML-patienter uden bivirkninger i dette forsøg med henblik på at reducere risikoen for vaskulære okklusive bivirkninger.
English: Iclusig treatment should be temporarily interrupted if hypertension is not medically controlled.
Danish: Iclusig-behandlingen bør midlertidigt seponeres, hvis hypertension ikke kan kontrolleres medicinsk.
English: Common erectile dysfunction
Danish: Almindelig erektil dysfunktion
English: Compared to healthy volunteers with normal liver function, no major differences in ponatinib PK were observed in patients with varying degrees of hepatic impairment.
Danish: Sammenlignet med raske frivillige forsøgspersoner med normal leverfunktion blev der ikke observeret nogen større forskelle i ponatinibs farmakokinetik hos patienter med forskellige grader af nedsat leverfunktion.
English: • a 45 mg film-coated tablet for the recommended dose.
Danish: • en 45 mg filmovertrukket tablet til den anbefalede dosis.
English: The recommended starting dose is 45 mg of ponatinib once daily.
Danish: Den anbefalede startdosis er 45 mg ponatinib én gang dagligt.
English: Cardiovascular status should continue to be monitored and medical and supportive therapy for conditions that contribute to cardiovascular risk should be optimised during treatment with ponatinib.
Danish: Den kardiovaskulære status skal fortsat overvåges, og medicinsk og understøttende behandling af tilstande, der øger den kardiovaskulær risiko, skal optimeres under behandlingen med ponatinib.
English: Serious bleeding events and haemorrhage, including fatalities, occurred in Iclusig-treated patients.
Danish: Alvorlige blødningshændelser og hæmoragi, herunder dødelige tilfælde, er forekommet hos Iclusigbehandlede patienter.
English: A prior MCyR or better (MCyR, MMR, or CMR) to dasatinib or nilotinib was only achieved in 26% patients with CP-CML and a prior MaHR or better (MaHR, MCyR, MMR, or CMR) was only achieved in 21%, and 24% of AP-CML, and BP-CML/Ph+ALL patients, respectively.
Danish: Et tidligere MCyR eller bedre respons (MCyR, MMR eller CMR) på dasatinib eller nilotinib blev kun opnået hos 26 % af patienter med CP-CML og et tidligere MaHR eller bedre respons (MaHR, MCyR, MMR eller CMR) blev kun opnået hos 21 % og 24 % af hhv. AP-CML- og BP-CML/Ph+ALL-patienter.
English: Iclusig is indicated in adult patients with
Danish: Iclusig er indiceret til behandling af voksne patienter med
English: In juvenile rats, mortality related to inflammatory effects was observed in animals treated with 3 mg/kg/day, and reductions in body weight gain were observed at doses of 0.75, 1.5 and 3 mg/kg/day during the pre weaning and early post weaning treatment phases.
Danish: Hos unge rotter blev der observeret mortalitet relateret til inflammatoriske virkninger hos dyr behandlet med 3 mg/kg/dag, og nedsat øgning af legemsvægt blev observeret ved doser på 0,75, 1,5 og 3 mg/kg/dag i behandlingsfaserne før fravænning og tidligt efter fravænning.
English: The safety and efficacy of Iclusig in CML and Ph+ ALL patients who were resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy were evaluated in a single-arm, open-label, international, multicenter trial.
Danish: Iclusigs sikkerhed og effekt hos CML- og Ph+ ALL-patienter, som var resistente eller intolerante over for tidligere behandling med tyrosin-kinase-hæmmere (TKI), blev evalueret i et enkeltarmet, åbent, internationalt, multicenter forsøg.
English: For all patients in the phase 2 trial, the dose intensity-safety relationship indicated that there are significant increases in grade ≥ 3 adverse events (cardiac failure, arterial thrombosis, hypertension, thrombocytopenia, pancreatitis, neutropenia, rash, ALT increase, AST increase, lipase increase, myelosuppression) over the dose range of 15 to 45 mg once-daily.
Danish: For alle patienter i fase 2-forsøget indicerede dosisstørrelses-sikkerhedsforholdet, at der er en signifikant stigning i grad ≥ 3 bivirkninger (hjerteinsufficiens, arterietrombose, hypertension, trombocytopeni, pancreatitis, neutropeni, udslæt, forhøjet ALAT, forhøjet ASAT, forhøjet lipase, myelosuppression) over dosisområdet 15-45 mg én gang dagligt.
English: Before starting treatment with ponatinib, the cardiovascular status of the patient should be assessed, including history and physical examination, and cardiovascular risk factors should be actively managed.
Danish: Før behandling med ponatinib indledes, skal patientens kardiovaskulære status vurderes, herunder anamnese og helbredsundersøgelse, og kardiovaskulære risikofaktorer skal håndteres aktivt.
English: In rats, inflammatory changes accompanied by increases in neutrophils, monocytes, eosinophils, and fibrinogen levels were found in the preputial and clitoral glands following chronic dosing.
Danish: Hos rotter konstateredes der inflammatoriske ændringer ledsaget af forhøjelser i neutrofil-, monocyt-, eosinofil- og fibrinogenniveauer i glandulae preputiales og clitorales efter kronisk dosering.
English: • a history of alcohol abuse
Danish: • har eller tidligere har haft et alkoholmisbrug
English: • fatigue, accumulation of fluid in arms and/or legs, fever, pain
Danish: • træthed, ophobning af væske i arme og/eller ben, feber, smerter
English: Iclusig has been evaluated in safety pharmacology, repeat-dose toxicity, genotoxicity, reproductive toxicity, and phototoxicity studies.
Danish: Iclusig er vurderet i sikkerhedsfarmakologiske studier, studier med gentagen dosering, gentoksicitets-, reproduktionstoksicitets- og fototoksicitetsstudier.
English: Common blood bilirubin increased, blood alkaline phosphatase increased, gammaglutamyltransferase increased
Danish: Almindelig forhøjet blodbilirubin, forhøjet alkalisk fosfatase i blodet, forhøjet gammaglutamyltransferase
English: Handling:
Danish: Håndtering:
English: Iclusig has a minor influence on the ability to drive and use machines.
Danish: Iclusig påvirker i mindre grad evnen til at føre motorkøretøj og betjene maskiner.
English: In the case of severe adverse reactions, treatment should be withheld.
Danish: I tilfælde af alvorlige bivirkninger skal behandlingen seponeres.
English: Factors to take into account if considering dose reduction in CP-CML patients who have achieved a MCyR in the absence of an adverse event.
Danish: Hvilke faktorer der skal tages i betragtning, hvis dosisreduktion hos CP-CMLpatienter, som har opnået MCyR uden en bivirkning, overvejes.
English: • heart problems, including heart failure, irregular heartbeats, and QT prolongation
Danish: • har hjerteproblemer, herunder hjertesvigt, uregelmæssig hjerterytme eller QT-forlængelse
English: A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Danish: A. FREMSTILLERANSVARLIG FOR BATCHFRIGIVELSE B.
English: • blood clot in a deep vein, sudden vein obstruction, blood clot in a blood vessel of the lung (symptoms include: hot flush, flushing, redness of the face, breathing difficulty)
Danish: • blodprop i en dyb vene, pludselig blokering af en vene, blodprop i en blodåre i lungen (blandt symptomerne er: hedeture, rødmen, rødmen i ansigtet, åndenød)
English: In CP-CML patients who achieved MCyR, the median time to MCyR was 84 days (range: 49 to 334 days) and in patients who achieved MMR, the median time to MMR was 167 days (range: 55 to 421 days).
Danish: Hos CP-CML-patienter, som opnåede MCyR, var den mediane tid til MCyR 84 dage (interval: 49 til 334 dage), og hos patienter, som opnåede MMR, var den mediane tid til MMR 167 dage (interval: 55 til 421 dage).
English: Amylase increased
Danish: Forhøjet amylase
English: Of the CP-CML patients previously treated with one, two, or three prior TKIs, 81% (13/16), 61% (65/105), and 46% (66/143) achieved a MCyR while on Iclusig, respectively.
Danish: Ud af de CP-CML-patienter, som tidligere blev behandlet med én, to eller tre tidligere TKI'er, opnåede hhv. 81 % (13/16), 61 % (65/105) og 46 % (66/143) et MCyR under behandling med Iclusig.
English: Skin changes in the form of crusts, hyperkeratosis, or erythema were observed in toxicity studies in cynomolgus monkeys.
Danish: Hudforandringer i form af skorper, hyperkeratose eller erytem blev observeres i toksicitetsstudier hos cynomolgus-aber.
English: Monitoring for evidence of thromboembolism and vascular occlusion should be performed and Iclusig should be interrupted immediately in case of vascular occlusion.
Danish: Patienten skal overvåges for tegn på tromboemboli og vaskulær okklusion, og Iclusig skal omgående seponeres i tilfælde af vaskulær okklusion.
English: • methotrexate: a medicine to treat severe joint inflammation (rheumatoid arthritis), cancer and the skin disease psoriasis.
Danish: • methotrexat: et lægemiddel, der bruges til at behandle svær inflammation af led (gigt), kræft og hudsygdommen psoriasis
English: (95% CI) Major Cytogenetic Responsec
Danish: (95 % KI) ”Major” cytogenetisk responsc
English: Vascular occlusion (see section 4.2 and 4.4).
Danish: 4.2 og 4.4).
English: The rates of treatment-related adverse events resulting in discontinuation were 14% in CP-CML, 7% in APCML and 4% in BP-CML/Ph+ ALL.
Danish: Procenterne af behandlingsrelaterede bivirkninger, der medførte seponering, var 14 % hos CP-CML, 7 % hos AP-CML og 4 % hos BP-CML/Ph+ ALL.
English: In rats, embryo-foetal toxicity in the form of post-implantation loss, reduced foetal body weight, and multiple soft tissue and skeletal alterations were observed at maternal toxic dosages.
Danish: Hos rotter blev der observeret embryo-fostertoksicitet i form af post-implantationstab, nedsat fosterkropsvægt og flere misdannelser af blødt væv og skelet ved maternelle toksiske doseringer.
English: Serious vascular occlusion has occurred in patients treated with Iclusig, including cardiovascular, cerebrovascular and peripheral vascular events, and venous thrombotic events.
Danish: Svær vaskulær okklusion er forekommet hos patienter behandlet med Iclusig, herunder kardiovaskulære, cerebrovaskulære og perifere vaskulære hændelser og venøse trombotiske hændelser.
English: • phenobarbital, phenytoin: medicines to treat epilepsy.
Danish: • phenobarbital, phenytoin: lægemidler, der bruges til at behandle epilepsi
English: Overall arterial and venous occlusive adverse reactions have occurred in 23% of Iclusig-treated patients from the phase 2 trial, with serious adverse reactions occurring in 18% of patients.
Danish: Generelt forekom arterielle og venøse okklusive bivirkninger hos 23 % af Iclusig-behandlede patienter fra fase 2-forsøget, og alvorlige bivirkninger forekom hos 18 % af patienterne.
English: The median duration of treatment with Iclusig was 866 days in CP-CML patients, 590 days in AP-CML patients, and 86 days in BP-CML/Ph+ ALL patients.
Danish: Den mediane behandlingsvarighed med Iclusig var 866 dage for patienter med CP-CML, 590 dage for patienter med AP-CML og 86 dage for patienter med BP-CML/Ph+ ALL.
English: An in vitro study in human hepatocytes indicated that clinical medicinal product interactions are also unlikely to occur as a result of ponatinib-mediated induction of the metabolism of substrates for CYP1A2, CYP2B6, or CYP3A.
Danish: Et in vitro-studie af humane hepatocytter tyder på, at det også er usandsynligt, at der vil være kliniske lægemiddelinteraktioner som følge af ponatinib-medieret induktion af metabolismen af substrater for CYP1A2, CYP2B6 eller CYP3A.
English: Women of childbearing potential/Contraception in males and females Women of childbearing age being treated with Iclusig should be advised not to become pregnant and men being treated with Iclusig should be advised not to father a child during treatment.
Danish: Kvinder i den fertile alder/kontraception hos mænd og kvinder Kvinder i den fertile alder, som behandles med Iclusig, skal rådes til at undgå graviditet, og mænd, der behandles med Iclusig, skal frarådes at gøre kvinder gravide.
English: Of 43 CP-CML patients, 31 CP-CML patients achieved a MCyR with a median duration of follow-up of 25.3 months (range: 1.7 to 38.4 months).
Danish: Ud af 43 patienter med CP-CML opnåede 31 patienter med CP-CML et MCyR med en median opfølgningsvarighed på 25,3 måneder (mellem 1,7 og 38,4 måneder).
English: In vitro studies indicate that clinical medicinal product interactions are unlikely to occur as a result of ponatinib-mediated inhibition of the metabolism of substrates for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A or CYP2D6.
Danish: In vitro-studier tyder på, at det er usandsynligt, at der vil være kliniske lægemiddelinteraktioner som følge af ponatinib-medieret hæmning af metabolismen af substrater for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A eller CYP2D6.
English: • lethargy, migraine
Danish: • letargi, migræne
English: Fatal and serious heart failure or left ventricular dysfunction occurred in Iclusig-treated patients, including events related to prior vascular occlusive events.
Danish: Dødelig og alvorlig hjerteinsufficiens eller nedsat funktion af venstre ventrikel er forekommet hos Iclusig-behandlede patienter, herunder hændelser relateret til tidligere vaskulære okklusive hændelser.
English: • circulatory problems in the spleen
Danish: • kredsløbsproblemer i milten
English: The adverse reactions described in this section were identified in a single-arm, open-label, international, multicenter trial in 449 CML and Ph+ ALL patients who were resistant or intolerant to prior TKI therapy including those with a BCR-ABL T315I mutation.
Danish: Bivirkningerne, der er beskrevet i dette punkt, blev identificeret i et enkeltarmet, åbent, internationalt, multicenter forsøg med 449 patienter med CML og Ph+ ALL, der var resistente eller intolerante overfor tidligere TKI-behandling, herunder personer med en BCR-ABL T315I-mutation.
English: Do not take Iclusig • if you are allergic to ponatinib or any of the other ingredients of this medicine (listed in section 6).
Danish: • hvis du er allergisk over for ponatinib eller et af de øvrige indholdsstoffer i dette lægemiddel
English: Riverbridge House Guildford Road
Danish: Guildford Road
English: • digoxin: a medicine to treat heart weakness.
Danish: • digoxin: et lægemiddel, der bruges til at behandle et svagt hjerte
English: Surrey KT22 9AD, United Kingdom
Danish: Leatherhead, Surrey KT22 9AD, Storbritannien
English: Resistant or Intolerant R/I Cohort (N=10)
Danish: Resistent eller intolerant R/I kohorte (N=10)
English: The secondary efficacy endpoints in AP-CML and BP-CML/Ph+ ALL were MCyR and MMR.
Danish: Det sekundære effektendepunkt hos AP-CML og BP-CML/Ph+ ALL var MCyR og MMR.
English: Patients were assigned to one of six cohorts based on disease phase (CP-CML; AP-CML; or BP-CML/Ph+ ALL), resistance or intolerance (R/I) to dasatinib or nilotinib, and the presence of the T315I mutation.
Danish: Patienter blev fordelt i én af seks kohorter baseret på sygdomsfase (CP-CML, AP-CML eller BP-CML/Ph+ ALL), resistens og intolerans (R/I) over for dasatinib eller nilotinib og tilstedeværelsen af T315I-mutation.
English: • increased or reduced sense of touch or sensation, abnormal sensation such as prickling, tingling and itchiness
Danish: • øget eller nedsat følsomhed over for berøring, unormal fornemmelse på huden som f.eks.
English: Iclusig should not be used in patients with a history of myocardial infarction, prior revascularization or stroke, unless the potential benefit of treatment outweighs the potential risk (see sections 4.2 and 4.8).
Danish: Iclusig bør ikke anvendes til patienter med myokardieinfarkt, tidligere revaskulariserende indgreb eller apopleksi i anamnesen, medmindre patientens potentielle nytte af behandlingen vejer tungere end risikoen (se pkt.
English: The primary efficacy endpoint in CP-CML was major cytogenetic response (MCyR), which included complete and partial cytogenetic responses (CCyR and PCyR).
Danish: Det primære effektendepunkt hos CP-CML var ”major” cytogenetisk respons (MCyR), som inkluderede komplet og delvist cytogenetisk respons (CCyR og PCyR).
English: Bottles of Iclusig 45 mg contain either 30 or 90 film-coated tablets.
Danish: Flasker med Iclusig 45 mg indeholder enten 30 eller 90 filmovertrukne tabletter.
English: • Consider discontinuing Iclusig
Danish: • Overvej at seponere Iclusig
English: Glucose increased
Danish: Forhøjet glucose
English: ANC* < 1.0 x 109/L or platelet < 50 x 109/L
Danish: ANC* < 1,0 x 109/l eller trombocyttal < 50 x 109/l
English: CP-CML patients who experienced a loss of response or development of a kinase domain mutation in the absence of a complete cytogenetic response or progression to AP-CML or BP-CML at any time on dasatinib or nilotinib were also considered resistant.
Danish: CP-CML-patienter, som oplevede manglende respons eller udvikling af en kinase-domæne-mutation ved fravær af komplet cytogenetisk respons eller progression til AP-CML eller BP-CML på et hvilket som helst tidspunkt under behandling med dasatinib eller nilotinib, blev også anset for at være resistente.
English: • chronic myeloid leukaemia (CML): a blood cancer involving too many abnormal white blood cells in the blood and the bone marrow (where blood cells are formed).
Danish: • kronisk myeloid leukæmi (CML): en form for blodkræft med for mange unormale hvide blodlegemer i blodet og knoglemarven, hvor blodlegemer dannes.
English: It is not known if Iclusig passes into breast milk.
Danish: Det vides ikke, om Iclusig udskilles i human mælk.
English: Bottles of Iclusig 15 mg contain either 60 or 180 film-coated tablets.
Danish: Flasker med Iclusig 15 mg indeholder enten 60 eller 180 filmovertrukne tabletter.
English: In addition, the pharmacokinetic-pharmacodynamic models show no exposure-effect relationship, with an estimated QTcF mean change of -6.4 ms (upper confidence interval -0.9 ms) at Cmax for the 60 mg group.
Danish: Endvidere viser de farmakokinetiske-farmakodynamiske modeller intet eksponeringseffektforhold med en estimeret gennemsnitlig ændring i QTcF på -6,4 msek.
English: Ponatinib-related microscopic findings in the ovaries (increased follicular atresia) and testes (minimal germ cell degeneration) in animals treated with 5 mg/kg ponatinib were noted in repeat-dose toxicity studies in cynomolgus monkeys.
Danish: Ponatinib-relaterede mikroskopiske fund i ovarier (forhøjet follikulær atresi) og testes (minimal spermatozo-degeneration) hos dyr, der blev behandlet med 5 mg/kg ponatinib, blev konstateret i toksicitetsstudier med gentagen dosering hos cynomolgus-aber.
English: Adverse reactions such as lethargy, dizziness, and vision blurred have been associated with Iclusig.
Danish: Bivirkning som f.eks. letargi, svimmelhed og sløret syn er blevet forbundet med Iclusig.
English: Very common alanine aminotransferase increased, aspartate aminotransferase increased
Danish: Meget almindelig forhøjet alaninaminotrasferase, forhøjet aspartataminotransferase
English: • a liver or pancreas disorder or reduced kidney function.
Danish: • har en sygdom i leveren eller bygspytkirtlen eller nedsat nyrefunktion.
English: • ketoconazole, itraconazole, voriconazole: medicines to treat fungal infections.
Danish: • ketoconazol, itraconazol, voriconazol: lægemidler, der bruges til at behandle svampeinfektioner
English: In a study in rats, diffuse corneal edema with neutrophilic cell infiltration, and hyperplastic changes in the lenticular epithelium suggestive of a mild phototoxic reaction were observed in animals treated with 5 and 10 mg/kg ponatinib
Danish: I et studie med rotter blev der observeret diffus corneaødem med neutrofilcelleinfiltration og hyperplastiske forandringer i linseepitelet, hvilket tyder på en mild fototoksisk reaktion hos dyr, behandlet med 5 og 10 mg/kg ponatinib
English: Intolerance was defined as the discontinuation of dasatinib or nilotinib due to toxicities despite optimal management in the absence of a complete cytogenetic response for CP CML patients or major haematological response for AP CML, BP CML, or Ph+ ALL patients.
Danish: Intolerans blev defineret som seponering af dasatinib eller nilotinib på grund af toksiciteter til trods for optimal behandling ved fravær af komplet cytogenetisk respons for CP CML-patienter eller ”major” hæmatologisk respons for AP CML-, BP CML- eller Ph+ ALL-patienter.
English: • had a prior heart attack or stroke
Danish: • har haft et hjerteanfald eller slagtilfælde
English: With once daily dosing, plasma exposures of ponatinib are increased by approximately 1.5-fold between first dose andsteady state conditions.
Danish: Med en dosis én gang dagligt øges plasmaeksponeringerne for ponatinib ca. 1,5 gang mellem første dosis og steady state tilstande.
English: Table 6 Efficacy of Iclusig in resistant or intolerant chronic phase CML patients Overall (N=267)
Danish: Tabel 6 Effekt af Iclusig hos resistente og intolerante CML-patienter i kronisk fase Generelt (N=267)
English: Caution should be exercised with concurrent use of Iclusig and moderate and strong CYP3A inhibitors and moderate and strong CYP3A inducers (see section 4.5).
Danish: Der skal udvises forsigtighed ved samtidig brug af Iclusig og moderate og stærke CYP3A-hæmmere (se pkt.
English: • nefazodone: a medicine to treat depression.
Danish: • nefazodon: et lægemiddel, der bruges til at behandle depression
English: • you develop heart or blood vessel problems.
Danish: • du får problemer med dit hjerte eller blodårer.
English: In vitro, ponatinib is an inhibitor of P-gp and BCRP.
Danish: In vitro hæmmer ponatinib P-gp og BCRP.